Allarity Therapeutics announces dismissal of securities class action lawsuit against all defendants

Allarity Therapeutics, Inc.

Securities class action filed Sept 13, 2024, alleging false statements on Dovitinib NDA prospects dismissed with prejudice.
No settlement or payment was made by the Company or officers in connection with dismissal.
CEO Thomas Jensen says dismissal allows focus on Phase 2 trial of stenoparib for advanced ovarian cancer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.